KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to -$762.1 million.

  • Gsk's Capital Expenditures fell 795.89% to -$762.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.8 billion, marking a year-over-year increase of 71.41%. This contributed to the annual value of -$1.8 billion for FY2025, which is 59.59% up from last year.
  • Latest data reveals that Gsk reported Capital Expenditures of -$762.1 million as of Q4 2025, which was down 795.89% from -$419.6 million recorded in Q3 2025.
  • Over the past 5 years, Gsk's Capital Expenditures peaked at -$259.0 million during Q1 2022, and registered a low of -$1.3 billion during Q4 2021.
  • For the 5-year period, Gsk's Capital Expenditures averaged around -$446.7 million, with its median value being -$374.6 million (2023).
  • Per our database at Business Quant, Gsk's Capital Expenditures surged by 6061.57% in 2022 and then crashed by 3017.89% in 2023.
  • Over the past 5 years, Gsk's Capital Expenditures (Quarter) stood at -$1.3 billion in 2021, then soared by 60.62% to -$504.4 million in 2022, then crashed by 30.18% to -$656.6 million in 2023, then decreased by 7.52% to -$705.9 million in 2024, then decreased by 7.96% to -$762.1 million in 2025.
  • Its last three reported values are -$762.1 million in Q4 2025, -$419.6 million for Q3 2025, and -$341.5 million during Q2 2025.